BE2017C009I2 - - Google Patents

Info

Publication number: BE2017C009I2
Authority: BE; Belgium

Application number

BE2017C009C

Other languages

Original Assignee

Millennium Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-14

Filing date

2017-04-11

Publication date

2017-09-22

2017-04-11 Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc

2017-09-22 Publication of BE2017C009I2 publication Critical patent/BE2017C009I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Pulmonology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Mycology (AREA)
Microbiology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Transplantation (AREA)
Cardiology (AREA)
Pregnancy & Childbirth (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Gynecology & Obstetrics (AREA)

BE2017C009C 2000-04-14 2017-04-11 BE2017C009I2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US55008200A	2000-04-14	2000-04-14
US09/748,960 US20010046496A1 (en)	2000-04-14	2000-12-27	Method of administering an antibody

Publications (1)

Publication Number	Publication Date
BE2017C009I2 true BE2017C009I2 (en)	2017-09-22

Family

ID=27069332

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BE2017C009C BE2017C009I2 (en)	2000-04-14	2017-04-11

Country Status (15)

Country	Link
US (5)	US20010046496A1 (en)
EP (3)	EP2298348B9 (en)
JP (3)	JP2003531129A (en)
AU (1)	AU2001251629A1 (en)
BE (1)	BE2017C009I2 (en)
CA (1)	CA2406220C (en)
CY (3)	CY1113489T1 (en)
DK (2)	DK2298348T3 (en)
ES (2)	ES2609689T3 (en)
FR (1)	FR14C0080I2 (en)
LU (1)	LUC00014I2 (en)
MX (1)	MXPA02010059A (en)
NL (1)	NL300702I2 (en)
PT (1)	PT2298348T (en)
WO (1)	WO2001078779A2 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7658924B2 (en)	2001-10-11	2010-02-09	Amgen Inc.	Angiopoietin-2 specific binding agents
US7521053B2 (en)	2001-10-11	2009-04-21	Amgen Inc.	Angiopoietin-2 specific binding agents
ES2531852T3 (en) *	2002-02-25	2015-03-20	Biogen Idec Ma Inc.	Administration of agents for the treatment of inflammation
GB0210121D0 (en)	2002-05-02	2002-06-12	Celltech R&D Ltd	Biological products
US8153768B2 (en)	2002-05-02	2012-04-10	Wyeth Holdings Corporation	Calicheamicin derivative-carrier conjugates
MX350383B (en) *	2004-01-09	2017-09-04	Pfizer	ANTIBODIES AGAINST MADCAM.
JP5062887B2 (en)	2004-09-03	2012-10-31	ジェネンテック，インコーポレイテッド	Humanized anti-β7 antagonists and uses thereof
PE20070374A1 (en) *	2005-07-08	2007-05-12	Pfizer Ltd	ANTI-MADCAM ANTIBODIES
WO2007007152A2 (en) *	2005-07-11	2007-01-18	Pfizer Limited	Anti-madcam antibodies to treat metastatic cancers and chloroma
KR20080017094A (en) *	2005-07-11	2008-02-25	화이자 리미티드	Novel combinations of anti-MADCAM antibodies and antifibrotic caspase inhibitors for treating liver fibrosis
AU2008204433B2 (en) *	2007-01-11	2014-03-13	Novo Nordisk A/S	Anti-KIR antibodies, formulations, and uses thereof
JP2010521966A (en) *	2007-03-20	2010-07-01	ミレニアム・ファーマシューティカルズ・インコーポレイテッド	Nucleic acid encoding humanized immunoglobulin that binds to α4β7 integrin
US20110105724A1 (en) *	2007-08-16	2011-05-05	Stephanie Jane Clegg	Novel compounds
JO2913B1 (en)	2008-02-20	2015-09-15	امجين إنك,	Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
CA2723614C (en) *	2008-05-16	2015-07-14	Genentech, Inc.	Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
MX2011009897A (en)	2009-03-20	2011-12-08	Amgen Inc	Alpha-4-beta-7 heterodimer specific antagonist antibody.
US8822663B2 (en)	2010-08-06	2014-09-02	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
DE19177059T1 (en)	2010-10-01	2021-10-07	Modernatx, Inc.	RIBONUCLEIC ACID CONTAINING N1-METHYL-PSEUDOURACILE AND USES
DE12722942T1 (en)	2011-03-31	2021-09-30	Modernatx, Inc.	RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS
UY34054A (en) *	2011-05-02	2012-11-30	Millennium Pharm Inc	FORMULATION FOR ANTI-A ANTIBODY (alpha) 4B (Beta) 7
UA116189C2 (en) *	2011-05-02	2018-02-26	Мілленніум Фармасьютікалз, Інк.	COMPOSITION OF ANTI-α4β7 ANTIBODY
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
KR20190099538A (en)	2011-10-03	2019-08-27	모더나 세라퓨틱스, 인코포레이티드	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
AU2012340621B2 (en) *	2011-11-23	2017-10-12	Amgen Inc.	Administration of alpha4beta7 hetero-dimer-specific antibody
EP2791160B1 (en)	2011-12-16	2022-03-02	ModernaTX, Inc.	Modified mrna compositions
EA034583B1 (en) *	2012-01-12	2020-02-21	Милленниум Фармасьютикалз, Инк.	USES OF ANTI-α4β7 ANTIBODY
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
CA2868393A1 (en)	2012-04-02	2013-10-10	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of oncology-related proteins and peptides
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9878056B2 (en)	2012-04-02	2018-01-30	Modernatx, Inc.	Modified polynucleotides for the production of cosmetic proteins and peptides
SI2922554T1 (en)	2012-11-26	2022-06-30	Modernatx, Inc.	Terminally modified rna
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
US10023626B2 (en)	2013-09-30	2018-07-17	Modernatx, Inc.	Polynucleotides encoding immune modulating polypeptides
BR112016007255A2 (en)	2013-10-03	2017-09-12	Moderna Therapeutics Inc	polynucleotides encoding low density lipoprotein receptor
JP2017537105A (en)	2014-11-26	2017-12-14	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Bedolizumab for the treatment of Crohn's disease with fistula
JP6904905B2 (en)	2014-12-24	2021-07-21	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Predicting the outcome of treatment with anti-α4β7 integrin antibody
JP2019508448A (en)	2016-03-14	2019-03-28	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Methods of graft versus host disease prevention
JP2019512493A (en)	2016-03-14	2019-05-16	ミレニアムファーマシューティカルズ，インコーポレイテッドＭｉｌｌｅｎｎｉｕｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	Methods of treatment or prevention of graft versus host disease
TW201735949A (en)	2016-03-24	2017-10-16	千禧製藥公司	Methods of treating gastrointestinal immune-related adverse events in anti-CTLA4 anti-PD-1 combination treatments
MA44483A (en)	2016-03-24	2019-01-30	Millennium Pharm Inc	METHODS FOR TREATING GASTROINTESTINAL ADVERSE EVENTS OF IMMUNE ORIGIN IN ONCOLOGICAL IMMUNE TREATMENTS
JP7162533B2 (en)	2016-05-04	2022-10-28	ミレニアムファーマシューティカルズ，インコーポレイテッド	Triple therapy for the treatment of inflammatory bowel disease
CA3027286A1 (en)	2016-06-12	2017-12-21	Millennium Pharmaceuticals, Inc.	Method of treating inflammatory bowel disease
KR102787394B1 (en)	2017-07-14	2025-03-26	화이자 인크.	Antibodies to MAdCAM
US20230139938A1 (en) *	2021-09-21	2023-05-04	University Of South Carolina	Anti-CCL8 Antibodies and Treatment of Lung Injury by CCL8 Inhibition
TW202504919A (en)	2023-05-30	2025-02-01	美商派拉岡醫療公司	Α4β7 integrin antibody compositions and methods of use
WO2024252368A2 (en)	2023-06-09	2024-12-12	Takeda Pharmaceutical Company Limited	Methods and compositions for treating ulcerative colitis

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4172124A (en)	1978-04-28	1979-10-23	The Wistar Institute	Method of producing tumor antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
DE3883899T3 (en) *	1987-03-18	1999-04-22	Sb2, Inc., Danville, Calif.	CHANGED ANTIBODIES.
EP0623679B1 (en)	1987-05-21	2003-06-25	Micromet AG	Targeted multifunctional proteins
US5538724A (en) *	1987-08-11	1996-07-23	The Board Of Trustees For The Leland Stanford Junior Univ.	Method of control leukocyte extravasation
US5403919A (en) *	1987-08-11	1995-04-04	Board Of Trustees Of The Leland Stanford Junior University Stanford University	Method to control leukocyte extravasation
WO1989007142A1 (en)	1988-02-05	1989-08-10	Morrison Sherie L	Domain-modified constant region antibodies
GB8823869D0 (en)	1988-10-12	1988-11-16	Medical Res Council	Production of antibodies
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
ATE139258T1 (en)	1990-01-12	1996-06-15	Cell Genesys Inc	GENERATION OF XENOGENE ANTIBODIES
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
DE69233482T2 (en)	1991-05-17	2006-01-12	Merck & Co., Inc.	Method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
LU91067I2 (en) *	1991-06-14	2004-04-02	Genentech Inc	Trastuzumab and its variants and immunochemical derivatives including immotoxins
WO1993006213A1 (en)	1991-09-23	1993-04-01	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
US5871734A (en) *	1992-01-13	1999-02-16	Biogen, Inc.	Treatment for asthma with VLA-4 blocking agents
US5932214A (en) *	1994-08-11	1999-08-03	Biogen, Inc.	Treatment for inflammatory bowel disease with VLA-4 blockers
CA2155303C (en) *	1993-02-09	2010-04-20	Linda C. Burkly	Treatment for insulin dependent diabetes
CA2115811A1 (en)	1993-02-17	1994-08-18	Claus Krebber	A method for in vivo selection of ligand-binding proteins
JPH08511420A (en)	1993-06-16	1996-12-03	セルテック・セラピューテイクス・リミテッド	Body
US5840299A (en)	1994-01-25	1998-11-24	Athena Neurosciences, Inc.	Humanized antibodies against leukocyte adhesion molecule VLA-4
GB2292079B (en) *	1994-08-12	1998-07-15	Flexpharm Ltd	Coated prednisolone preparation for the treatment of inflamatory bowel disease
US6551593B1 (en) *	1995-02-10	2003-04-22	Millennium Pharmaceuticals, Inc.	Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US6015662A (en) *	1996-01-23	2000-01-18	Abbott Laboratories	Reagents for use as calibrators and controls
US7147851B1 (en)	1996-08-15	2006-12-12	Millennium Pharmaceuticals, Inc.	Humanized immunoglobulin reactive with α4β7 integrin
AU5702298A (en)	1996-12-03	1998-06-29	Abgenix, Inc.	Transgenic mammals having human Ig loci including plural VH and VK regions nd antibodies produced therefrom
CN1236815C (en) *	1998-09-14	2006-01-18	德克萨斯州立大学董事会	Application of integrin antagonist in preparation of medicine for treating multiple myeloma and bone resorption induced by myeloma

2000
- 2000-12-27 US US09/748,960 patent/US20010046496A1/en not_active Abandoned
2001
- 2001-04-13 WO PCT/US2001/012234 patent/WO2001078779A2/en active Application Filing
- 2001-04-13 AU AU2001251629A patent/AU2001251629A1/en not_active Abandoned
- 2001-04-13 EP EP10010997.4A patent/EP2298348B9/en not_active Expired - Lifetime
- 2001-04-13 EP EP16191558.2A patent/EP3167902B1/en not_active Revoked
- 2001-04-13 ES ES10010997.4T patent/ES2609689T3/en not_active Expired - Lifetime
- 2001-04-13 ES ES01925028T patent/ES2398096T3/en not_active Expired - Lifetime
- 2001-04-13 CA CA2406220A patent/CA2406220C/en not_active Expired - Lifetime
- 2001-04-13 DK DK10010997.4T patent/DK2298348T3/en active
- 2001-04-13 DK DK01925028.1T patent/DK1278543T3/en active
- 2001-04-13 MX MXPA02010059A patent/MXPA02010059A/en active IP Right Grant
- 2001-04-13 EP EP01925028A patent/EP1278543B1/en not_active Expired - Lifetime
- 2001-04-13 PT PT100109974T patent/PT2298348T/en unknown
- 2001-04-13 JP JP2001576078A patent/JP2003531129A/en not_active Withdrawn
2003
- 2003-12-15 US US10/735,863 patent/US20050095238A1/en not_active Abandoned
2011
- 2011-08-05 US US13/204,139 patent/US20120034243A1/en not_active Abandoned
2012
- 2012-05-02 JP JP2012105379A patent/JP5764524B2/en not_active Expired - Lifetime
- 2012-12-18 CY CY20121101236T patent/CY1113489T1/en unknown
2014
- 2014-02-03 US US14/171,161 patent/US20140186345A1/en not_active Abandoned
- 2014-11-11 NL NL300702C patent/NL300702I2/nl unknown
- 2014-11-13 FR FR14C0080C patent/FR14C0080I2/en active Active
- 2014-11-17 CY CY2014046C patent/CY2014046I2/en unknown
2015
- 2015-01-19 JP JP2015007655A patent/JP6021959B2/en not_active Expired - Lifetime
2017
- 2017-01-05 CY CY20171100013T patent/CY1118429T1/en unknown
- 2017-04-11 LU LU00014C patent/LUC00014I2/fr unknown
- 2017-04-11 BE BE2017C009C patent/BE2017C009I2/nl unknown
2018
- 2018-11-02 US US16/179,157 patent/US20200002423A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20050095238A1 (en)	2005-05-05
CY2014046I1 (en)	2016-04-13
CA2406220C (en)	2019-02-12
US20140186345A1 (en)	2014-07-03
US20120034243A1 (en)	2012-02-09
EP2298348B9 (en)	2017-02-15
CA2406220A1 (en)	2001-10-25
HK1054320A1 (en)	2003-11-28
MXPA02010059A (en)	2004-08-19
CY1113489T1 (en)	2016-04-13
JP6021959B2 (en)	2016-11-09
DK1278543T3 (en)	2013-01-14
WO2001078779A3 (en)	2002-07-04
LUC00014I2 (en)	2017-06-19
WO2001078779A2 (en)	2001-10-25
CY2014046I2 (en)	2016-04-13
NL300702I1 (en)	2016-01-28
LUC00014I1 (en)	2017-04-18
ES2609689T3 (en)	2017-04-21
EP1278543A2 (en)	2003-01-29
ES2398096T3 (en)	2013-03-13
FR14C0080I2 (en)	2015-10-30
US20010046496A1 (en)	2001-11-29
US20200002423A1 (en)	2020-01-02
JP2003531129A (en)	2003-10-21
EP2298348B1 (en)	2016-10-12
EP2298348A1 (en)	2011-03-23
DK2298348T3 (en)	2017-01-30
FR14C0080I1 (en)	2014-12-19
JP2015083603A (en)	2015-04-30
EP1278543B1 (en)	2012-09-19
NL300702I2 (en)	2016-01-28
EP3167902B1 (en)	2020-07-29
PT2298348T (en)	2017-01-04
JP5764524B2 (en)	2015-08-19
EP3167902A1 (en)	2017-05-17
JP2012184241A (en)	2012-09-27
CY1118429T1 (en)	2017-06-28
AU2001251629A1 (en)	2001-10-30

Publication	Publication Date	Title
BE2017C009I2 (en)	2017-09-22
BE2014C035I2 (en)	2020-08-20
BE2012C026I2 (en)	2020-12-15
BE2011C041I2 (en)	2020-08-20
JP2002537716A5 (en)	2005-06-23
BRPI0113372A8 (en)	2003-06-24
BY5768C1 (en)	2003-12-30
CN3139849S (en)	2000-02-23
CN3141752S (en)	2000-03-15
AU2000264849A8 (en)	2002-02-21
AU2000278563A8 (en)	2001-12-06
AU2000278679A8 (en)	2002-06-27
AU2000280388A8 (en)	2003-02-20
BY6855C1 (en)	2000-10-31
CL2006000179A1 (en)	2006-11-17
CN3133795S (en)	2000-01-05
CN3135640S (en)	2000-01-19
CN3135789S (en)	2000-01-26
CN3135921S (en)	2000-01-26
CN3135930S (en)	2000-01-26
CN3136262S (en)	2000-01-26
CN3139026S (en)	2000-02-16
CN3139578S (en)	2000-02-23
AU2000256023A8 (en)	2001-11-29
CN3139997S (en)	2000-03-01